US Archives - Page 26 of 111 - European Medical Journal

Phase III Trial Results: Nerandomilast in Pulmonary Fibrosis

In a Phase III clinical trial, nerandomilast, an oral phosphodiesterase 4B inhibitor, was associated with a smaller decline in lung function over 52 weeks in patients with progressive pulmonary fibrosis, when compared with placebo.

Invasive Candidiasis Management Gaps in ICUs Shared in 2024 Survey

Invasive candidiasis remains a significant challenge for intensive care units worldwide due to its high mortality rate, diagnostic complexity, and increasing resistance.

Osteoarthritis Surgery Reviewed: Risks, Results, and Recommendations

Surgical intervention for severe osteoarthritis continues to be a critical decision point in orthopedics.

Sexual Behavior Strongest Driver of Gut Microbiome in HIV

In a new study that challenges conventional assumptions about gut health in people living with HIV, researchers have found that sexual behavior has a stronger association with gut microbiome composition than either antiretroviral therapy (ART) regimens or weight changes.

Precision Approaches in Colorectal Cancer: Interview with John Strickler

It has been known for years that there is a small subgroup of patients with colorectal cancer who have HER2-positive disease…

The Evolving Standard of Care in Advanced Biliary Tract Cancers

This infographic presents three-year follow-up data from the TOPAZ-1 trial; the first global Phase III study to evaluate an immuno…

Silent Threat: Third Cancers After Prostate Cancer Raise Mortality Risk

Prostate cancer survivors face a long-term threat that often goes undetected, a third primary cancer, according to new findings that highlight an under-recognized but serious risk with significant survival implications.

What Ambient AI Means for Epilepsy Clinics

Healthcare professionals and neurologists across the U.S. are closely watching the emergence of ambient AI tools in clinical practice, especially as these technologies enter specialized settings like epilepsy care.

GLP-1 Drugs May Curb Weight Gain After Quitting Smoking

GLP-1 receptor agonists (GLP-1 RAs), widely recognized for their role in metabolic disorders, may offer added support for smokers attempting to quit, according to findings presented at the 2025 American Psychiatric Association Annual Meeting.

1 in 10 Liver Transplant Patients Still Break Bones Despite Protocol

Liver transplant patients face a substantial risk of bone fractures despite following specialized care protocols, according to new findings.